English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Sarcopenia is a potentially reversible condition, which requires proper screening and diagnosis.    Aims  To validate a Polish version of sarcopenia screening questionnaire (SARC-F), and assess its clinical performance.    Methods  Cross-sectional validation study in community-dwelling subjects ≥ 65 years of age. Diagnosis of sarcopenia was based on the 2018 2nd European Working Group on Sarcopenia in Older People (EWGSOP2) consensus. Hand grip and 4-m gait speed were measured, and the Polish version of SARC-F was administered.    Results  The mean (SD) age of 73 participants (21.9% men) was 77.8 (7.3) years. Seventeen participants (23.3%) fulfilled the EWGSOP2 criteria of sarcopenia, and 9 (12.3%) criteria for severe sarcopenia. Fourteen (19.2%) participants fulfilled the SARC-F criteria for clinical suspicion of sarcopenia. The Cronbach’s alpha coefficient for internal was 0.84. With EWGSOP2 sarcopenia as a gold standard, the sensitivity of SARC-F was 35.3% (95% CI 14.2–61.7,  p  = 0.33), specificity was 85.7% (95% CI 73.8–93.6,  p  < 0.0001). The corresponding positive and negative predictive values were 42.9% ( p  = 0.79) and 81.4% ( p  < 0.0001), respectively. The probability of false-positive result was 14.3% (95% CI 6.4–26.2,  p  < 0.0001) and the probability of false-negative result was 64.7% (95% CI 38.3–85.8,  p  = 0.33). Overall the predictive power of SARC-F was low (c-statistic 0.64).    Discussion  SARC-F is currently recommended for sarcopenia case finding in general population of older adults. However, its sensitivity is low, despite high specificity.    Conclusions  At present SARC-F is better suited to rule out sarcopenia then to case-finding. Further refinement of screening for sarcopenia with the use of SARC-F seems needed.    Supplementary Information  The online version contains supplementary material available at 10.1007/s40520-020-01782-y.

SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards